QuidelOrtho Corporation (LON:0A55)
London
· Delayed Price · Currency is GBP · Price in USD 43.50
-0.14 (-0.31%)
At close: Jan 31, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2014 - 2019 |
Labs | 1.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Labs Growth | 2.22% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Point of Care | 694.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Point of Care Growth | -11.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Molecular Diagnostics | 24.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Molecular Diagnostics Growth | -11.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Immunohematology | 522.60M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Immunohematology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Donor Screening | 115.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Donor Screening Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2014 - 2019 |
North America Adjusted EBITDA | 892.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America Adjusted EBITDA Growth | 0.02% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA Adjusted EBITDA | 46.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA Adjusted EBITDA Growth | -19.94% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Adjusted EBITDA | 130.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Adjusted EBITDA Growth | 6.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Adjusted EBITDA | 133.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Adjusted EBITDA Growth | 4.05% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Corporate Adjusted EBITDA | -659.70M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Corporate Adjusted EBITDA Growth | 6.59% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2014 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 29, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 2, 2022 | Jan '21 Jan 3, 2021 | 2014 - 2019 |
North America | 1.62B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
North America Growth | -7.85% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA | 335.80M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EMEA Growth | 2.75% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China | 325.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
China Growth | 2.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies | 502.30M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Geographies Growth | 4.14% |
Log In |
Log In |
Log In |
Log In | Upgrade
|